RT Journal Article
SR Electronic
T1 Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.17.21259078
DO 10.1101/2021.06.17.21259078
A1 Whittaker, Charles
A1 Watson, Oliver J.
A1 Alvarez-Moreno, Carlos
A1 Angkasekwinai, Nasikarn
A1 Boonyasiri, Adhiratha
A1 Triana, Luis Carlos
A1 Chanda, Duncan
A1 Charoenpong, Lantharita
A1 Chayakulkeeree, Methee
A1 Cooke, Graham S.
A1 Croda, Julio
A1 Cucunubá, Zulma M
A1 Djaafara, Bimandra A.
A1 Estofolete, Cassia F.
A1 Grillet, Maria Eugenia
A1 Faria, Nuno R.
A1 Costa, Silvia Figueiredo
A1 Forero-Peña, David A.
A1 Gibb, Diana M.
A1 Gordon, Anthony C
A1 Hamers, Raph L.
A1 Hamlet, Arran
A1 Irawany, Vera
A1 Jitmuang, Anupop
A1 Keurueangkul, Nukool
A1 Kimani, Teresia Njoki
A1 Lampo, Margarita
A1 Levin, Anna S.
A1 Lopardo, Gustavo
A1 Mustafa, Rima
A1 Nayagam, Shevanthi
A1 Ngamprasertchai, Thundon
A1 Hannah Njeri, Ng’ang’a Irene
A1 Nogueira, Mauricio L.
A1 Ortiz-Prado, Esteban
A1 Perroud, Mauricio W.
A1 Phillips, Andrew N.
A1 Promsin, Panuwat
A1 Qavi, Ambar
A1 Rodger, Alison J.
A1 Sabino, Ester C.
A1 Sangkaew, Sorawat
A1 Sari, Djayanti
A1 Sirijatuphat, Rujipas
A1 Sposito, Andrei C.
A1 Srisangthong, Pratthana
A1 Thompson, Hayley A.
A1 Udwadia, Zarir
A1 Valderrama-Beltrán, Sandra
A1 Winskill, Peter
A1 Ghani, Azra C.
A1 Walker, Patrick G.T.
A1 Hallett, Timothy B.
YR 2021
UL http://medrxiv.org/content/early/2021/06/20/2021.06.17.21259078.abstract
AB Background The unprecedented public health impact of the COVID-19 pandemic has motivated a rapid search for potential therapeutics, with some key successes. However, the potential impact of different treatments, and consequently research and procurement priorities, have not been clear.Methods and Findings We develop a mathematical model of SARS-CoV-2 transmission, COVID-19 disease and clinical care to explore the potential public-health impact of a range of different potential therapeutics, under a range of different scenarios varying: i) healthcare capacity, ii) epidemic trajectories; and iii) drug efficacy in the absence of supportive care. In each case, the outcome of interest was the number of COVID-19 deaths averted in scenarios with the therapeutic compared to scenarios without. We find the impact of drugs like dexamethasone (which are delivered to the most critically-ill in hospital and whose therapeutic benefit is expected to depend on the availability of supportive care such as oxygen and mechanical ventilation) is likely to be limited in settings where healthcare capacity is lowest or where uncontrolled epidemics result in hospitals being overwhelmed. As such, it may avert 22% of deaths in high-income countries but only 8% in low-income countries (assuming R=1.35). Therapeutics for different patient populations (those not in hospital, early in the course of infection) and types of benefit (reducing disease severity or infectiousness, preventing hospitalisation) could have much greater benefits, particularly in resource-poor settings facing large epidemics.Conclusions There is a global asymmetry in who is likely to benefit from advances in the treatment of COVID-19 to date, which have been focussed on hospitalised-patients and predicated on an assumption of adequate access to supportive care. Therapeutics that can feasibly be delivered to those earlier in the course of infection that reduce the need for healthcare or reduce infectiousness could have significant impact, and research into their efficacy and means of delivery should be a priority.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCW is supported by a Medical Research Council Doctoral Training Partnership Studentship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and outputs relevant to the analysis are available at https://github.com/mrc-ide/apothecary. https://github.com/mrc-ide/apothecary